Topline and subgroup results from the ESLIM‑01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association #EHA24 Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online. https://lnkd.in/gphtawRw
HUTCHMED
Biotechnology Research
Building a global science-focused biopharma from an established base in China.
About us
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us here on LinkedIn.
- Website
-
https://www.hutch-med.com
External link for HUTCHMED
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Hong Kong
- Type
- Public Company
- Founded
- 2000
- Specialties
- Pharmaceutical, Biopharmaceutical, Innovation, Research and Development, Oncology, Hematology, Immunology, Inflammation, Cancer, and Targeted Therapy
Locations
-
Primary
Metropolis Tower, 10 Metropolis Drive, Hung Hom
Level 18
Hong Kong, HK
-
917 Halei Road, Building 4, Zhangjiang Hi-Tech Park
Pudong, Shanghai 201203, CN
-
25A Vreeland Road
Suite 304
Florham Park, NJ 07932, US
Employees at HUTCHMED
Updates
-
We are pleased to share that we have initiated the RAPHAEL registrational Phase III trial of HMPL-306 in patients with mutated IDH1/2 relapsed/refractory acute myeloid leukemia in China. https://lnkd.in/gKmqqcyB
-
We are happy to announce the initiation of a Phase II/III trial of the combination of surufatinib, camrelizumab (Hengrui Pharma's PD-1 antibody), nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in China. PDAC is an exocrine tumor and the most common form of pancreatic cancer, with almost half a million people diagnosed each year across the globe. https://lnkd.in/gztdgWcC
-
We are pleased to share that our partner Takeda has received positive CHMP Opinion for a new treatment for adults with previously treated metastatic #ColorectalCancer #mCRC throughout the European Union, Norway, Liechtenstein and Iceland. Learn More:https://lnkd.in/gnwjpgCR
-
New and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research Annual Meeting 2024 #AACR24 , taking place on April 5-10, 2024 in San Diego, California. https://lnkd.in/gMNzSavN
-
We are happy to share that, in collaboration with Innovent Biologics, the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for the treatment of patients with advanced endometrial cancer has been accepted and granted priority review by the China National Medical Products Administration. https://lnkd.in/ghYRFhFr
-
The supplemental New Drug Application (sNDA) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration. If approved, the new label indication for savolitinib will be expanded to include treatment-naive patients in China. https://lnkd.in/guMVw_nH
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic
https://www.hutch-med.com
-
We are pleased to announce that we have initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China. wAIHA is an autoimmune disorder that can lead to anemia and has limited treatment options. This follows positive data from the proof-of-concept Phase II stage of the trial and subsequent consultation with the China National Medical Products Administration. If positive, the data from the trial may be used to support a future New Drug Application filing. https://lnkd.in/g2NfJt-k
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in Chi
https://www.hutch-med.com
-
2023 was an important year for HUTCHMED. We made significant progress and executed against our commitment to bring our innovative medicines to patients worldwide, while remaining dedicated to becoming a self-sustaining business. Today, we are happy to report our 2023 Full Year Financial Results: https://lnkd.in/deweff_c
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
https://www.hutch-med.com
Similar pages
Browse jobs
Stock
HCM
NASDAQ
20 minutes delay
$20.17
-0.79 (-3.769%)
- Open
- 20.5
- Low
- 20.06
- High
- 20.5
Data from Refinitiv
See more info on